<DOC>
	<DOC>NCT00861380</DOC>
	<brief_summary>The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S. pneumoniae or H. influenzae as well as vaccine impact on the occurrence of hospital-diagnosed pneumonia cases, tympanostomy tube placement and outpatient antimicrobial prescriptions. This study will also explore vaccine impact on occurrence of respiratory tract infections (RTIs), including acute otitis media (AOM) in a subset of children in Turku area.</brief_summary>
	<brief_title>Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease</brief_title>
	<detailed_description>The protocol posting has been updated with regards to the enrolment of subjects and outcome measures following Protocol amendment 2, 22 August 2011.</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female between, and including, 6 weeks to 18 months of age at the time of the first vaccination. Written informed consent obtained from parent(s) or from the guardian(s) of the subject. Previous vaccination with any registered, nonregistered or investigational pneumococcal vaccine other than the study vaccine, or planned use during the study period. If a child belongs to a high risk group for pneumococcal infections for which a licensed pneumococcal conjugate vaccine is made locally available, the subject can not be enrolled in the study and should be referred to the specific immunization program. Previous vaccination against Hepatitis B virus with any registered, nonregistered or investigational vaccine, or planned use of such a vaccine other than the study vaccine during the study period. Previous vaccination against Hepatitis A virus with any registered, nonregistered or investigational vaccine, or planned use of such a vaccine other than the study vaccine during the study period. Known severe hypersensitivity to any component of the study vaccines, including neomycin. Any medical condition that would contraindicate the initiation of routine immunization outside a clinical trial context.</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pneumococcal conjugate vaccine</keyword>
	<keyword>Invasive disease</keyword>
	<keyword>Respiratory tract infections</keyword>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Acute otitis media</keyword>
	<keyword>Pneumonia</keyword>
</DOC>